Description
Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs[1].–20°C (Powder, sealed storage, away from moisture and light)-Applications–Formula-C52H85N7O12S-Citation–References-[1]Wang Y, et al. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety. Cancers (Basel). 2020 Mar 21;12(3):744.-CASNumber–MolecularWeight-1032.34-Compound Purity-99.85-SMILES-CC[C@@H]([C@H](N(C)C([C@@H](NC([C@@H](N(C)C(CCCCCN1C(C(CC1=O)SC[C@@H](C(O)=O)N)=O)=O)C(C)C)=O)C(C)C)=O)[C@H](OC)CC(N2[C@H]([C@H](OC)[C@H](C(N[C@@H]([C@H](C3=CC=CC=C3)O)C)=O)C)CCC2)=O)C-Research_Area-Cancer-Solubility-DMSO : 100 mg/mL (ultrasonic)-Target-Drug-Linker Conjugates for ADC-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related
